I
n this issue, Hull and colleagues (1) report on their trial examining venous thromboembolism (VTE) prophylaxis in medical patients. An interim analysis of this trial, performed after enrollment of more than 3000 patients at 370 sites in 20 countries, found a lower-than-anticipated VTE rate (symptomatic or asymptomatic) in those treated with standard enoxaparin prophylaxis (3.3%). In a different context, one might have expected the trial's sponsor, which markets enoxaparin, to have been pleased. However, because this trial was designed to test extended-duration enoxaparin, these results may not have been a cause for celebration. For new therapies, especially those with risks for serious harms, demonstrating benefit is highly dependent on a sufficiently high control rate (2) . Rather than simply conclude that standard enoxaparin is highly effective and that the incremental benefits of prolonged therapy would be unlikely to outweigh the additional bleeding risk, the investigators instead set out to identify a subgroup of patients with a higher VTE rate who might be likely to benefit from extended prophylaxis.
Notwithstanding the statistical issues raised by this interim peek at the data, the concern that the overall result may not apply to all patients is well founded. Patients enrolled in a trial often have very different risks for the outcome, and the net benefit of therapies that have serious treatment-related harm depends on this risk (3), so aggregating results across patients with different outcome risks may be misleading (4) . Subgroup analysis is often used to address this issue, but the subgroup results may also be misleading, especially when patients with different outcome risks are subgrouped together.
The Figure illustrates some of the issues at play for therapies with harms whose benefits can be highly sensitive to baseline outcome risks. In this simplified example, the outcome risks for all patients are determined by the presence or absence of 3 independent risk factors that identify 8 equal-sized subgroups. For the purposes of this discussion, assume that a treatment-favorable risk-benefit ratio depends on achieving an outcome rate in the control group of at least 4.5%-the overall rate that Hull and colleagues observed after the protocol amendment. However, much like the outcome rate found at the time of the interim analysis, the assumptions described in the figure result in an overall risk of just under 3.4% (the arithmetic mean across all 8 possible risk combinations). Thus, a trial that enrolled patients with this risk distribution would yield unfavorable summary results. Nevertheless, subgroup analyses might reveal groups who were at sufficiently high risk to benefit from therapy.
A conventional subgroup analysis, such as one that examined for example risk factor X ( Figure) , would find that persons with this risk factor have an outcome rate of 4.5%-which suggests that such patients are at high risk and should be treated. Similar analyses would demonstrate that patients with risk factors Y and Z benefit as well. These sequential, one-variable-at-a-time subgroup analyses would suggest that all patients should be treated, except for those without any risk factors (who comprise just one eighth of the trial population). What this type of analysis would obscure is that three quarters of the patients included in any of the so-called high-risk groups have outcome risks lower than the 4.5% threshold for net benefit. Furthermore, even though 3 sequential subgroup analyses would show that patients with risk factor X, or Y, or Z have an average risk of 4.5%, when analyzed in aggregate, these "high-risk" patients (with at least 1 risk factor) have an average risk of only 3.7%, which is well below the threshold. Thus, recommendations that are based on the one-variable-ata-time analyses would result in net harm. This paradox results from the repeated inclusion of the highest-risk group-the only group that benefits-in each of the sequential, one- The risk distribution in the figure is generated from the following assumptions: 3 risk factors (X, Y, and Z), each of which doubles outcome risk, has a prevalence of 50% and assorts independently. The base risk (with no risk factors) is 1%. If treatment were justified for patients with an outcome risk of 4.5% or greater, sequential one-variable-at-a-time subgroup analyses (on risk factor X, or Y, or Z) would suggest that patients with any one of these risk factors might benefit, together comprising seven eighths of patients. Subgrouping based on a multivariable risk score would demonstrate that only one eighth of patients is at sufficiently high risk to warrant therapy.
variable-at-at-time analyses, each time grouped with a different set of lower-risk patients who do not benefit. Alternatively, an analysis that categorizes patients by using a multivariate risk score (as represented by the different shades of green), instead of individual risk factors, would clearly show that treatment benefit is limited only to patients who have all 3 risk factors. This analysis would support treatment of only one eighth of the patients, instead of seven eighths, and yield a greater net benefit by avoiding exposure to the treatment-related harms that outweigh the benefits in lower-risk patients.
Even in this highly simplified example, subgroups that would seem to be at sufficient risk to warrant therapy could be created in several ways. In the absence of guidelines on how best to assess and report treatment-effect heterogeneity, this is generally left to the discretion of the sponsors and investigators. However, it can be in the sponsor's interest to enlarge the treatment-favorable population by including lower-risk patients, as long as the aggregate riskbenefit ratio remains favorable.
So how do these hypothetical considerations help with the interpretation of the many subgroup analyses in this trial? First, in the absence of strong evidence that relative treatment effects vary across patients, the outcome rate in the control group of the various subgroups, together with the overall effect, is likely to be more informative than the treatment effect in each of the subgroups (5), which are individually underpowered to yield precise estimates of treatment effects. Second, we should recognize that the primary subgroups reported in the trial were carefully designed during the interim analysis to yield overall outcome rates near the required target, while still including many patients at substantially lower risk. The more finely disaggregated results reported in Table 5 of the study report make it clear that the VTE event rates for patients younger than 75 years are less than 4% in all groups and less than 3% in most, even those with so-called high-risk features. Third, once we shift our focus from the overall population to subgroups, it becomes apparent that better, multivariate risk models are critically needed to facilitate rational decision making for therapies with both incremental risks and benefits (such as extended-duration enoxaparin). The risk model developed during this interim analysis is a start but is insufficient in itself.
Given that only 1 in 4 VTE events was symptomatic, a 4.5% treatment threshold is probably insufficiently conservative. If approximately one third of all VTEs are prevented at a cost of 1 major hemorrhage for every 200 patients treated, then simple math shows that an underlying VTE rate after in-hospital prophylaxis of approximately 6% is required simply to trade 1 symptomatic VTE (without extended enoxaparin) for 1 major hemorrhage (with extended enoxaparin). This is approximately the outcome rate in the group of patients older than 75 years in Hull and colleagues' trial. Although some might consider this a reasonable trade-off, we suspect that most clinicians would not be enthusiastic about extending therapy unless it prevented at least 2 or 3 symptomatic events for each major complication. The subgroup of highest-risk older patients might approach this threshold, but only if the observed higher relative treatment effects in that subgroup apply.
Hull and colleagues' trial highlights the need for better VTE risk models that more precisely target patients with the best chance of benefiting from new and existing prophylactic strategies (6) . More generally, we need to reach consensus regarding the best way to routinely assess and report treatment-effect heterogeneity in both positive and negative trials, particularly for treatments with serious harms. Because a more individualized approach usually means smaller markets for the new therapy, it is imperative to require rigorous and transparent risk stratification.
